Exercise Reduced Cardiovascular Events in Survivors of Childhood Lymphoma

Article

Survivors of childhood Hodgkin lymphoma who went on to regularly complete vigorous exercise had a lower risk of cardiovascular events later in life.

Survivors of childhood Hodgkin lymphoma who went on to regularly complete vigorous exercise had a lower risk of cardiovascular events, independent of their cardiovascular risk profile, than those survivors who did not exercise regularly.

In fact, a study published in the Journal of Clinical Oncology showed that those survivors who had more than 9 metabolic equivalent (MET) hours per week of exercise had less than half of the risk of those survivors with 0 MET hours.

“Our findings indicate that adoption of regular exercise consistent with national vigorous exercise recommendations in currently sedentary survivors could confer substantial public health benefits in the rapidly growing population of survivors of childhood cancer,” wrote study author Lee W. Jones, PhD, of Memorial Sloan Kettering Cancer Center, and colleagues.

Prior research has proven that survivors of childhood Hodgkin lymphoma are at an increased risk for premature cardiovascular morbidity and mortality. For this reason, various preventive strategies have been researched in this patient population.

In this study, Jones and colleagues hypothesized that exercise would reduce the risk of major cardiovascular events in a dose-dependent manner. To assess this theory, they studied 1,187 survivors of Hodgkin lymphoma who completed a questionnaire evaluating vigorous-intensity exercise. Exercise was calculated in MET hours per week. The primary endpoint of the study was incidence of any major cardiovascular events.

During a median of 11.9 years of follow-up, 135 cardiovascular events occurred. Among survivors reporting 0 MET hours, the incidence of any cardiovascular event at 10 years was 12.2% compared with 5.2% for those reporting 9 or more MET hours.

After multivariable analysis that adjusted for age, race, smoking, cardiovascular risk factors, anthracycline use, and chest radiation exposure, the researchers found an inverse relationship between total amount of vigorous exercise and the incidence of cardiovascular events. Patients who met the guidelines of maintaining vigorous exercise for 9 or more MET hours had an adjusted 51% decreased risk for any cardiovascular events compared with those getting less than 9 MET hours.

“Our data create a strong rationale for the development of a systematic research agenda to investigate the efficacy of aerobic exercise to prevent and/or delay treatment-associated cardiovascular toxicity in survivors of Hodgkin lymphomas,” the researchers wrote. “Important currently unanswered questions include identification of the optimal timing (during and/or after treatment exposure), as well as intensity and dose of exercise to prevent/delay cardiovascular toxicity.”

Recent Videos
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Investigators are currently evaluating mosunetuzumab in relapsed disease or comparing it with rituximab in treatment-naïve follicular lymphoma.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
Related Content